[go: up one dir, main page]

MX2023012651A - Novedosas composiciones y metodos de n,n-dimetiltriptamina. - Google Patents

Novedosas composiciones y metodos de n,n-dimetiltriptamina.

Info

Publication number
MX2023012651A
MX2023012651A MX2023012651A MX2023012651A MX2023012651A MX 2023012651 A MX2023012651 A MX 2023012651A MX 2023012651 A MX2023012651 A MX 2023012651A MX 2023012651 A MX2023012651 A MX 2023012651A MX 2023012651 A MX2023012651 A MX 2023012651A
Authority
MX
Mexico
Prior art keywords
dmt
dimethyltryptamine
methods
novel compositions
exhibiting
Prior art date
Application number
MX2023012651A
Other languages
English (en)
Inventor
Srinivas Rao
Gleen Short
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of MX2023012651A publication Critical patent/MX2023012651A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una composición que incluye N,N-dimetiltriptamina (DMT) o una sal farmacéuticamente aceptable de esta capaz de exhibir un nivel sanguíneo terapéuticamente efectivo de DMT de entre aproximadamente 20 y aproximadamente 60 minutos cuando se administra a un ser humano. Un método para tratar una enfermedad o afección neurológica que comprende administrar por vía bucal, sublingual, subcutánea o intranasal a un sujeto que lo necesita una cantidad efectiva de DMT o una sal farmacéuticamente aceptable de esta, capaz de exhibir un nivel terapéuticamente efectivo de DMT de entre aproximadamente 20 a aproximadamente 60 minutos cuando se administra a un ser humano.
MX2023012651A 2021-04-26 2022-04-26 Novedosas composiciones y metodos de n,n-dimetiltriptamina. MX2023012651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163179679P 2021-04-26 2021-04-26
PCT/US2022/026396 WO2022232179A1 (en) 2021-04-26 2022-04-26 Novel n,n-dimethyltryptamine compositions and methods

Publications (1)

Publication Number Publication Date
MX2023012651A true MX2023012651A (es) 2023-11-06

Family

ID=83694712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012651A MX2023012651A (es) 2021-04-26 2022-04-26 Novedosas composiciones y metodos de n,n-dimetiltriptamina.

Country Status (12)

Country Link
US (1) US11602521B2 (es)
EP (1) EP4329879A4 (es)
JP (1) JP2024517738A (es)
KR (1) KR20240000516A (es)
CN (1) CN117320711A (es)
AU (1) AU2022267240A1 (es)
BR (1) BR112023022195A2 (es)
CA (1) CA3216889A1 (es)
CL (1) CL2023003191A1 (es)
IL (1) IL308074A (es)
MX (1) MX2023012651A (es)
WO (1) WO2022232179A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182156A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
WO2022261383A1 (en) 2021-06-09 2022-12-15 ATAI Life Sciences AG Novel prodrugs and conjugates of dimethyltryptamine
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
EP4499085A1 (en) * 2022-03-27 2025-02-05 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of social/emotional withdrawal or detachment
TW202423415A (zh) * 2022-10-26 2024-06-16 美商雅特益醫療公司 Ｎ－ｎ－二甲基色胺（ｄｍｔ）及ｄｍｔ類似物組合物、其製造方法及使用方法
DK202330319A1 (en) * 2023-11-07 2025-05-27 Fertin Pharma As An adhesive oral disc for sustained release of cannabinoids
KR20250163394A (ko) 2023-03-31 2025-11-20 사이빈 유케이 리미티드 모노아민 항우울제 및 단기 지속성 환각제를 포함하는 조합
WO2025054397A1 (en) * 2023-09-08 2025-03-13 Atai Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
WO2025076151A1 (en) * 2023-10-02 2025-04-10 Atai Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
CN114423422A (zh) 2019-02-22 2022-04-29 Gh研究爱尔兰有限公司 用于治疗精神障碍的含有5-甲氧基-n,n-二甲基色胺(5-meo-dmt)的组合物
ES2984438T3 (es) 2019-02-22 2024-10-29 Gh Res Ireland Limited 5-metoxi-N,N-dimetiltriptamina (5-meo-dmt) para el tratamiento de la depresión mayor
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
CA3182156A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
AU2021298118A1 (en) * 2020-06-22 2022-12-08 University Of Zürich Compositions and kits of parts comprising N,N-dimethyltryptamine and harmine and their use in therapy
CA3192617A1 (en) 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement

Also Published As

Publication number Publication date
IL308074A (en) 2023-12-01
EP4329879A1 (en) 2024-03-06
US11602521B2 (en) 2023-03-14
JP2024517738A (ja) 2024-04-23
EP4329879A4 (en) 2025-04-09
US20220339139A1 (en) 2022-10-27
CA3216889A1 (en) 2022-11-03
AU2022267240A1 (en) 2023-11-23
CL2023003191A1 (es) 2024-04-01
CN117320711A (zh) 2023-12-29
BR112023022195A2 (pt) 2024-01-16
KR20240000516A (ko) 2024-01-02
WO2022232179A9 (en) 2023-07-13
WO2022232179A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CL2023003191A1 (es) Novedosas composiciones y métodos de n,n-dimetiltriptamina
US7115252B2 (en) Therapeutic compositions and methods of use thereof
JP4194653B2 (ja) アフタ口内潰瘍に伴う痛みの即効的解放のための薬剤組成物
ATE304850T1 (de) Verfahren zur stiegerung des blutglukosespiegels in säugern
ES2170050T3 (es) Metodos y composiciones para inducir la ereccion.
Stecker et al. Should a mucoadhesive patch (DentiPatch) be used for gingival anesthesia in children?
RU2012136724A (ru) Лечение или профилактика инфекции
EA201992759A1 (ru) Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения
BR0008443A (pt) Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética
Paraskevas et al. Thromboangiitis obliterans (Buerger’s disease): searching for a therapeutic strategy
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
RU2550957C1 (ru) Способ лечения хронического генерализованного пародонтита
Bansal et al. Comparative evaluation of coronally advanced flap with and without bioactive glass putty in the management of gingival recession defects: a randomized controlled clinical trial
WO2000018380A1 (en) Prevention and treatment of parodontitis
EA200501456A1 (ru) Торий- 227 для применения в радиотерапии заболевания мягких тканей
US20040116521A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
Umeizudike et al. Severe presentation of necrotizing ulcerative periodontitis in a Nigerian HIV-positive patient: a case report
Al-Zarea et al. Efficacy of Myrrh Mouth Rinse vs. Chlorhexidine Mouth Rinse in Maintaining the Soft Tissue Health around Dental Implants: A Comparative Study.
CL2022002104A1 (es) Tratamiento de infección por coronavirus con interferón lambda
AR122160A1 (es) PROCEDIMIENTO PARA EL TRATAMIENTO DE UNA INFECCIÓN VIRAL CON a-1-ANTITRIPSINA HUMANA
RU2624867C1 (ru) Способ комплексного лечения больных с воспалительными заболеваниями пародонта
Butticaz et al. Evaluation of a nystatin-containing mouth rinse for terminally ill patients in palliative care
RU2605260C1 (ru) Способ комплексного лечения больных с воспалительными заболеваниями пародонта
RU2772298C1 (ru) Способ лечения хронического катарального гингивита с применением антисептической композиции
RU2705388C1 (ru) Способ лечения хронического генерализованного катарального гингивита